Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Non-Current Assets (2024 - 2025)

Historic Non-Current Assets for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $9.6 million.

  • Xilio Therapeutics' Non-Current Assets fell 1536.7% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year change of. This contributed to the annual value of $10.8 million for FY2024, which is N/A changed from last year.
  • Xilio Therapeutics' Non-Current Assets amounted to $9.6 million in Q3 2025, which was down 1536.7% from $10.1 million recorded in Q2 2025.
  • Xilio Therapeutics' Non-Current Assets' 5-year high stood at $13.4 million during Q1 2024, with a 5-year trough of $9.6 million in Q3 2025.